Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

The Hokusai-VTE Investigators*

ABSTRACT

BACKGROUND
Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.

METHODS
In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.

RESULTS
A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro–brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98).

CONCLUSIONS
Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.)
Venaous thromboembolism is the third most common cardiovascular disease after myocardial infarction and stroke, affecting at least 700,000 persons annually in North America.\(^1\) The standard treatment consists of low-molecular-weight heparin followed by vitamin K antagonists.\(^4\) A number of studies have established that new oral anticoagulants with or without initial heparin therapy are effective alternatives.\(^5\)\(^-\)\(^8\)

Edoxaban is a direct inhibitor of activated factor X with a rapid onset of action. It is administered orally once daily and has proven antithrombotic efficacy.\(^9\)\(^-\)\(^11\) The Hokusai-VTE study was a randomized, double-blind clinical trial that was conducted to evaluate edoxaban for the treatment of venous thromboembolism. The study was designed with the aim of broadening applicability to real-world practice and encouraging the enrollment of all patients, including those with extensive disease, by specifying that treatment should be initiated with the proven, global standard of parenteral heparin; that the dose of the study drug should be halved in patients perceived to be at higher risk for bleeding (e.g., those with renal impairment or low body weight); and that physicians should be allowed to adjust the duration of treatment according to the absence or presence of temporary risk factors, and the safety of patients with deep-vein thrombosis, pulmonary embolism, or both.\(^12\) A coordinating committee in collaboration with the sponsor (Daiichi Sankyo) was responsible for the design and oversight of the study and for developing the protocol. The institutional review board at each participating center approved the protocol. All patients provided written informed consent. The institutional review board at each participating center approved the protocol. All patients provided written informed consent. The sponsor was responsible for the collection and maintenance of the data. An independent committee, whose members were unaware of the study-group assignments, adjudicated all suspected outcomes and the results of baseline imaging tests and assessed the anatomical extent of thrombosis. An independent data and safety monitoring committee periodically reviewed study outcomes. The members of the writing committee wrote all drafts of the manuscript (no one who is not a named author contributed substantially to the manuscript), verified the data, and vouch for the completeness of the data, the accuracy of the analyses, and the fidelity of the study to the protocol. The protocol and accompanying documents are available with the full text of this article at NEJM.org.

**PATIENTS**

Patients 18 years of age or older were eligible if they had objectively diagnosed, acute, symptomatic deep-vein thrombosis involving the popliteal, femoral, or iliac veins or acute, symptomatic pulmonary embolism (with or without deep-vein thrombosis). Patients were excluded if they had contraindications to heparin or warfarin, had received treatment for more than 48 hours with therapeutic doses of heparin, had received more than one dose of a vitamin K antagonist, had cancer for which long-term treatment with low-molecular-weight heparin was anticipated, had another indication for warfarin therapy, continued to receive treatment with aspirin at a dose of more than 100 mg daily or dual antiplatelet therapy, or had creatinine clearance of less than 30 ml per minute. The full list of exclusion criteria is provided in the protocol.

**METHODS**

**STUDY OVERSIGHT**

In this randomized, double-blind trial, we compared heparin (enoxaparin or unfractionated heparin) followed by edoxaban with heparin followed by warfarin with respect to efficacy and safety in patients with deep-vein thrombosis, pulmonary embolism, or both.\(^12\) A coordinating committee in collaboration with the sponsor (Daiichi Sankyo) was responsible for the design and oversight of the study and for developing the protocol. The institutional review board at each participating center approved the protocol. All patients provided written informed consent. The sponsor was responsible for the collection and maintenance of the data. An independent committee, whose members were unaware of the study-group assignments, adjudicated all suspected outcomes and the results of baseline imaging tests and assessed the anatomical extent of thrombosis. An independent data and safety monitoring committee periodically reviewed study outcomes. The members of the writing committee wrote all drafts of the manuscript (no one who is not a named author contributed substantially to the manuscript), verified the data, and vouch for the completeness of the data, the accuracy of the analyses, and the fidelity of the study to the protocol. The protocol and accompanying documents are available with the full text of this article at NEJM.org.

**RANDOMIZATION AND STUDY TREATMENT**

Randomization was performed with the use of an interactive Web-based system, with stratification according to the qualifying diagnosis (deep-vein thrombosis or pulmonary embolism), presence or absence of temporary risk factors, and the dose of edoxaban. All patients received initial therapy with open-label enoxaparin or unfractionated heparin for at least 5 days.\(^12\) Edoxaban or warfarin was administered in a double-blind, double-dummy fashion.

Edoxaban (or placebo) was started after discontinuation of initial heparin. Edoxaban was administered at a dose of 60 mg orally once daily, taken with or without food, or at a dose of 30 mg once daily in patients with a creatinine clearance of 30 to 50 ml per minute or a body weight of 60 kg or less or in patients who were receiving concomitant treatment with potent P-glycoprotein inhibitors.

Warfarin (or placebo) was started concurrently...
with the study regimen of heparin, with adjustment of the dose to maintain the international normalized ratio (INR) between 2.0 and 3.0. All measurements were performed by means of a point-of-care device that provided an actual INR value for patients receiving warfarin and a sham INR value for patients receiving edoxaban. INR measurements were required to be performed at least monthly.

Treatment with edoxaban or warfarin was to be continued for at least 3 months in all patients and for a maximum of 12 months. The duration was determined by the treating physician on the basis of the patient’s clinical features and patient preference.

OUTCOME MEASURES
The primary efficacy outcome was the incidence of adjudicated symptomatic recurrent venous thromboembolism, which was defined as a composite of deep-vein thrombosis or nonfatal or fatal pulmonary embolism. Death was adjudicated as related to venous thromboembolism, other cardiovascular disease, bleeding, or other causes. Pulmonary embolism was considered to be the cause of death if there was objective documentation that a pulmonary embolism caused the death or if the death could not be attributed to a documented cause and pulmonary embolism could not be ruled out. Prespecified secondary efficacy outcomes included the primary efficacy outcome combined with either death from cardiovascular causes or death from any cause.

The principal safety outcome was the incidence of adjudicated clinically relevant bleeding, which was defined as a composite of major or clinically relevant nonmajor bleeding. Bleeding was defined as major if it was overt and was associated with a decrease in hemoglobin of 2 g per deciliter or more or required a transfusion of 2 or more units of blood, occurred in a critical site, or contributed to death. Clinically relevant nonmajor bleeding was defined as overt bleeding that did not meet the criteria for major bleeding but was associated with the need for medical intervention, contact with a physician, or interruption of the study drug or with discomfort or impairment of activities of daily life. Net clinical benefit was determined on the basis of the composite of symptomatic recurrent venous thromboembolism or major bleeding. The criteria for adjudication of outcomes are provided in the Supplementary Appendix, available at NEJM.org.

SURVEILLANCE AND FOLLOW-UP
Patients underwent assessment, in the clinic or by telephone, on days 5 through 12, 30, and 60 after randomization and monthly thereafter while they were taking the study drug or every 3 months after discontinuing the study drug. All patients were to be contacted at month 12. Patients were instructed to report symptoms suggestive of recurrent venous thromboembolism or bleeding. Appropriate diagnostic testing, laboratory testing, or both were required in patients with suspected events.

STATISTICAL ANALYSIS
The study was designed as an event-driven trial to test the hypothesis that edoxaban would be noninferior to warfarin with respect to the primary efficacy outcome, with an upper limit of the confidence interval for the hazard ratio of 1.5 and a two-sided alpha level of 0.05. This margin corresponds to retention of at least 70% of the treatment effect of warfarin.

Assuming equal efficacy of edoxaban and warfarin, we estimated that 220 events would need to occur for the study to have 85% power to show the noninferiority of edoxaban. When we determined that the targeted number of events was expected to be accrued, we set the date for concluding the study (study closure) such that the last patient who underwent randomization would complete 6 months of study treatment and follow-up. Assuming a 3% incidence of the primary efficacy outcome, we estimated that we would have to enroll at least 7500 patients.

All efficacy analyses were performed in the modified intention-to-treat population, which included all patients who underwent randomization and received at least one dose of the study drug. The primary analysis included all efficacy outcomes from randomization through the end of 12 months or study closure (overall study period), regardless of the duration of the patient’s study treatment. The time to the first primary efficacy outcome was analyzed with the use of a Cox proportional-hazards model with stratification factors as covariates. In addition, the primary efficacy outcome was evaluated for the on-treatment period — the time during which the patients were receiving the study drug or within 3 days after the study drug was stopped or interrupted.

Analyses of bleeding outcomes included patients who received at least one dose of the study drug
RESULTS

PATIENTS AND TREATMENT
From January 2010 through October 2012, a total of 8292 patients were enrolled at 439 centers in 37 countries (Fig. 1). The baseline characteristics of the patients were similar in the two study groups (Table 1). The median duration of heparin treatment after randomization was 7 days. Details of the actual duration of treatment with the study drug are provided in Table S2 in the Supplementary Appendix; 40% of patients were treated for 12 months. Adherence to edoxaban treatment was 80% or more in 99% of the patients in that group. Among patients receiving warfarin, the INR was in the therapeutic range for 63.5% of the time, above 3.0 for 17.6% of the time, and below 2.0 for 18.9% of the time.

RECURRENT VENOUS THROMBOEMBOLISM
A recurrence of venous thromboembolism during the overall study period occurred in 130 of 4118 patients (3.2%) in the edoxaban group and in 146 of 4122 patients (3.5%) in the warfarin group (hazard ratio with edoxaban, 0.89; 95% confidence interval [CI], 0.70 to 1.13; \( P < 0.001 \) for noninferiority). The difference in risk (edoxaban minus warfarin) was \(-0.39\) percentage points (95% CI, \(-1.16\) to 0.39). The types and time

---

Figure 1. Randomization and Follow-up.
The modified intention-to-treat and safety analyses included all patients who underwent randomization and received at least one dose of the study drug.
The upper limits of the 95% confidence intervals of the hazard ratios for recurrent venous thromboembolism in patients who presented with deep-vein thrombosis or pulmonary embolism did not exceed the prespecified margin of 1.5 (Table 2). Among patients with pulmonary embolism and evidence of right ventricular dysfunction (NT-proBNP level of ≥500 pg per milliliter),
Table 2. Clinical Outcomes during Overall Study Period and On-Treatment Period.*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Edoxaban (N = 4118)</th>
<th>Warfarin (N = 4122)</th>
<th>Hazard Ratio with Edoxaban (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary efficacy outcome: first recurrent VTE or VTE-related death — no./total no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event during overall study period</td>
<td>130/4118 (3.2)</td>
<td>146/4122 (3.5)</td>
<td>0.89 (0.70–1.13)</td>
<td>&lt;0.001 (for noninferiority)</td>
</tr>
<tr>
<td>Fatal PE</td>
<td>4/4118 (0.1)</td>
<td>3/4122 (0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death, with PE not ruled out</td>
<td>20/4118 (0.5)</td>
<td>21/4122 (0.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal PE with or without DVT</td>
<td>49/4118 (1.2)</td>
<td>59/4122 (1.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVT alone</td>
<td>57/4118 (1.4)</td>
<td>63/4122 (1.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event during on-treatment period</td>
<td>66/4118 (1.6)</td>
<td>80/4122 (1.9)</td>
<td>0.82 (0.60–1.14)</td>
<td>&lt;0.001 (for noninferiority)</td>
</tr>
<tr>
<td>Patients with index DVT</td>
<td>2468/4118 (59.9)</td>
<td>2453/4122 (59.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event during overall study period</td>
<td>83/2468 (3.4)</td>
<td>81/2453 (3.3)</td>
<td>1.02 (0.75–1.38)</td>
<td></td>
</tr>
<tr>
<td>Event during on-treatment period</td>
<td>48/2468 (1.9)</td>
<td>50/2453 (2.0)</td>
<td>0.96 (0.64–1.42)</td>
<td></td>
</tr>
<tr>
<td>Patients with index PE</td>
<td>1650/4118 (40.1)</td>
<td>1669/4122 (40.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event during overall study period</td>
<td>47/1650 (2.8)</td>
<td>65/1669 (3.9)</td>
<td>0.73 (0.50–1.06)</td>
<td></td>
</tr>
<tr>
<td>Event during on-treatment period</td>
<td>18/1650 (1.1)</td>
<td>30/1669 (1.8)</td>
<td>0.60 (0.34–1.08)</td>
<td></td>
</tr>
<tr>
<td><strong>Safety outcome during on-treatment period — no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary safety outcome: first major or clinically relevant nonmajor bleeding</td>
<td>349 (8.5)</td>
<td>423 (10.3)</td>
<td>0.81 (0.71–0.94)</td>
<td>0.004 (for superiority)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>56 (1.4)</td>
<td>66 (1.6)</td>
<td>0.84 (0.59–1.21)</td>
<td>0.35 (for superiority)</td>
</tr>
<tr>
<td>Fatal</td>
<td>2 (&lt;0.1)</td>
<td>10 (0.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial</td>
<td>0</td>
<td>6 (0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>1 (&lt;0.1)</td>
<td>2 (&lt;0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retroperitoneal</td>
<td>0</td>
<td>1 (&lt;0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (&lt;0.1)</td>
<td>1 (&lt;0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal in critical site</td>
<td>13 (0.3)</td>
<td>25 (0.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracranial</td>
<td>5 (0.1)</td>
<td>12 (0.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retroperitoneal</td>
<td>0</td>
<td>3 (0.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>8 (0.2)</td>
<td>10 (0.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal in noncritical site</td>
<td>41 (1.0)</td>
<td>33 (0.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinically relevant nonmajor bleeding</td>
<td>298 (7.2)</td>
<td>368 (8.9)</td>
<td>0.80 (0.68–0.93)</td>
<td>0.004 (for superiority)</td>
</tr>
<tr>
<td>Any bleeding</td>
<td>895 (21.7)</td>
<td>1056 (25.6)</td>
<td>0.82 (0.75–0.90)</td>
<td>&lt;0.001 (for superiority)</td>
</tr>
<tr>
<td><strong>Other adverse event — no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any adverse event occurring during on-treatment period</td>
<td>2821 (68.5)</td>
<td>2928 (71.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any serious adverse event</td>
<td>503 (12.2)</td>
<td>544 (13.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any serious adverse event leading to permanent discontinuation of the study drug</td>
<td>121 (2.9)</td>
<td>105 (2.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any drug-related adverse event leading to permanent discontinuation of the study drug</td>
<td>41 (1.0)</td>
<td>51 (1.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The primary efficacy and safety outcomes were assessed by means of time-to-first-event analyses. Patients could have more than one event. The overall study period was 12 months; the on-treatment period included the time during which the patients were receiving the study drug or within 3 days after the study drug was stopped or interrupted.
Bleeding Outcomes

Clinically relevant bleeding (major or nonmajor) occurred in 349 of 4118 patients (8.5%) in the edoxaban group and in 423 of 4122 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The difference in risk (edoxaban minus warfarin) was −1.8 percentage points (95% CI, −3.04 to −0.53). Major bleeding occurred in 56 patients (1.4%) in the edoxaban group and in 66 patients (1.6%) in the warfarin group (hazard ratio, 0.84; 95% CI, 0.59 to 1.21). The clinical presentation and time course of bleeding events are provided in Table 2 and Figure 3.

Among patients who qualified for the 30-mg dose of edoxaban, clinically relevant bleeding occurred in 58 of 733 patients (7.9%) who received edoxaban, and in 92 of the 719 patients (12.8%) who received warfarin (hazard ratio, 0.62; 95% CI, 0.44 to 0.86). Major bleeding occurred in 11 patients (1.5%) in the edoxaban group and in 22 patients (3.1%) in the warfarin group (hazard ratio, 0.50; 95% CI, 0.24 to 1.03). The hazard ratios for bleeding in the other prespecified subgroups are provided in Figure S2 in the Supplementary Appendix.

Deaths and Other Adverse Events

The number and causes of death, as well as results with respect to the net clinical benefit, are shown in Table S3 in the Supplementary Appendix. There were 21 acute coronary events in the edoxaban group (0.5%) and 16 in the warfarin group (0.4%). The rates of other adverse outcomes were also similar in the two groups. (Table 2, and Table S3 in the Supplementary Appendix.)
DISCUSSION

In this large, double-blind study involving patients with venous thromboembolism, treatment with heparin followed by oral edoxaban once daily, as compared with standard therapy, was noninferior with respect to efficacy and superior with respect to bleeding. We succeeded in enrolling patients across a broad spectrum of venous thromboembolic manifestations, ranging from limited proximal deep-vein thrombosis to severe pulmonary embolism, and the relative efficacy was observed throughout. In analyses of safety, the results were consistent with respect to both major bleeding and clinically relevant nonmajor bleeding, with fewer fatal and intracranial bleeds in the edoxaban group (Table 2), although the between-group difference with respect to major bleeding did not reach statistical significance.

Efficacy was evaluated at 12 months of follow-up, regardless of the duration of treatment — a study design that was different from that of earlier studies. The design of the Hokusai-VTE study, as compared with a design calling for on-treatment analyses only, allowed for a better understanding of the outcomes that may be expected in clinical practice. In the on-treatment analysis, we observed low rates of recurrence that were similar to those seen in contemporary studies. In our study, the relative efficacy of edoxaban was not limited to patients receiving medication, but it was evident even among those who stopped treatment before 12 months (Fig. 2).

Some aspects of our trial warrant comment. Three recent studies focused on a single-drug approach for all treatment phases. Thus, the use of the traditional sequence of a heparin lead-in followed by an oral agent may be considered a limitation of the Hokusai-VTE study. However, given the global acceptance of, and confidence in, initial parenteral treatment, the heparin lead-in encouraged investigators to enroll a high proportion of patients with severe grades of venous thromboembolism. When designing the study, we anticipated that a considerable proportion of patients with right ventricular dysfunction due to pulmonary embolism would be included. We measured NT-proBNP levels in all patients with pulmonary embolism and assessed right ventricular dimensions by means of computed tomography in a random subgroup of 1002 of these patients. Approximately one third had right ventricular dysfunction. There was a reduction in recurrences among patients with elevated NT-proBNP levels in the edoxaban group, and this finding was supported by the analysis of
patients with right ventricular dysfunction as assessed by means of computed tomography.

The study design aimed to address concerns that new oral anticoagulants may confer a higher risk of bleeding among patients with renal impairment and low body weight.12 We identified approximately one fifth of patients with these risk factors. Halving of the daily dose of edoxaban to 30 mg maintained efficacy with significantly less bleeding than that observed in the warfarin group.

To ensure best practice with the comparator, the quality of warfarin therapy was proactively monitored throughout the study. This resulted in an overall time in the therapeutic range of 63.5%, which is a higher percentage of time in the therapeutic range than the 40 to 50% seen in registries of clinical practice.20-22 Our findings are likely to be generalizable. In this global study, we included patients with both provoked and unprovoked venous thromboembolism, and treatment durations varied from 3 to 12 months at the discretion of the treating physician. Loss to follow-up was very low (<0.2%), as was the rate of withdrawal of consent (<0.9%).23

In conclusion, the Hokusai-VTE study showed that in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism, edoxaban administered once daily after initial heparin was noninferior to standard therapy with warfarin after initial heparin, with significantly less bleeding.

Supported by Daiichi-Sankyo.

Dr. Büller reports receiving consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Isis Pharmaceuticals, and ThromboGenics, and grant support from Bayer and Pfizer. Dr. Decousus reports receiving fees for board membership from Bayer and Daiichi Sankyo, lecture fees from GlaxoSmithKline, and grant support from Bayer, Bristol-Myers Squibb–Pfizer, Boehringer Ingelheim, and Portola. Drs. Grosso, Mercuri, Schwocho, and Shi report being employees of Daiichi Sankyo. Dr. Middeldorp reports receiving consulting fees from Bayer and Bristol-Myers Squibb–Pfizer, lecture fees from Bayer, GlaxoSmithKline, Bristol-Myers Squibb–Pfizer, and Boehringer Ingelheim, and grant support from GlaxoSmithKline, Bristol-Myers Squibb–Pfizer, and Sanquin.

Dr. Prins reports receiving consulting fees from Bayer, Pfizer, and Boehringer Ingelheim, and lecture fees from Bayer. Dr. Raskob reports receiving consulting fees and travel support from Bayer, Bristol-Myers Squibb, Janssen, Johnson & Johnson, Pfizer, Sanofi-Aventis, and Takeda. Dr. Schellong reports receiving consulting fees from Bayer and Boehringer Ingelheim, and lecture fees from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb–Pfizer.

Dr. Segers reports receiving fees for the scientific management of the studies as director of the International Clinical Trial Organization and Management (ICTOM) academic research organization from Bayer, Isis Pharmaceuticals, and Pfizer. Dr. Verhamme reports receiving consulting fees from Bayer, Boehringer Ingelheim, ThromboGenics, and Pfizer, lecture fees from Bayer, Boehringer Ingelheim, Leo Pharma, Sanofi-Aventis, and Pfizer, and grant support from Bayer, Boehringer Ingelheim, Leo Pharma, and Sanofi-Aventis. Dr. Wells reports receiving lecture fees from Bayer, Boehringer Ingelheim, Biomerieux, and Bristol-Myers Squibb–Pfizer. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Sunny Cho, Min Lin, Gregg Lovelace, and George Zhang for their assistance in the analyses and manuscript preparation.

The affiliations of the members of the writing committee are as follows: the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam (H.R.B., S.M.); INSERM CIE3, University of Saint Etienne, Centre Hospitalier Universitaire, Saint-Etienne, France (H.D.); Daiichi Sankyo Pharma Development, Edison, NJ (M.A.G., M.M., L.S., M.S.); the Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa (P.W.).

REFERENCES


